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Abstract 
Purpose: To determine the mechanism underlying the anti-hyperprolactinemia effects of Radix bupleuri 
extract (RBE) in rats.  
Methods: Rats were divided into six groups (n=10 each group): healthy controls, untreated 
hyperprolactinemic rats, hyperprolactinemic rats treated with bromocriptine (0.6 mg/kg), and 
hyperprolactinemic rats treated with RBE (4.8, 9.6, or 19.2 g/kg). After 30 days, hypothalamic protein 
levels of dopamine D2 receptor, protein kinase A (PKA), and cyclic adenosine monophosphate (cAMP) 
were determined.  
Results: Dopamine D2 receptor levels were lower in untreated hyperprolactinemic rats than in healthy 
controls (p < 0.01), but this decrease was attenuated by RBE (p < 0.05). Elevated PKA levels in 
untreated hyperprolactinemic rats (0.61 ± 0.04 µg/ml, p < 0.01) were decreased by RBE (4.8 g/kg, 0.42 
± 0.03 µg/ml, p < 0.05; 9.6 g/kg, 0.33 ± 0.02 µg/ml, p < 0.01; 19.2 g/kg, 0.27 ± 0.03 µg/ml, p < 0.01). 
Similarly, elevated cAMP levels in hyperprolactinemic rats (2.4 ± 0.4 ng/ml) were decreased by RBE 
(4.8 g/kg, 1.8 ± 0.3 ng/ml, p < 0.05; 9.6 g/kg, 1.5 ± 0.3 ng/ml, p < 0.01; 19.2 g/kg, 1.2 ± 0.2 ng/ml, p < 
0.01). 
Conclusions: RBE anti-hyperprolactinemia activity is mediated by dopamine D2 receptor signaling via 
the cAMP/PKA pathway. 
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Hyperprolactinemia is a heterogeneous disorder 
characterized by elevated blood prolactin level. 
This disorder of the hypothalamic-pituitary axis 
can have a physiological cause (e.g., 
pregnancy), pathological cause (e.g., tumor), or 
unknown cause (i.e., idiopathic 
hyperprolactinemia). In different patients, 
similarly elevated prolactin levels can result in 
severe clinical manifestations or no symptoms at 
all [1]. Hyperprolactinemia is more common in 
women than in men. Its prevalence in an 
unselected adult population is 0.4 % but has 
been reported as 5 % in women visiting a family 
planning clinic, 9 % in women with adult-onset 
amenorrhea, and 17 % in women with polycystic 
ovary syndrome [2,3]. The two most commonly 
prescribed drugs for the treatment of 
hyperprolactinemia are bromocriptine and 
cabergoline. These medications are dopamine 
receptor agonists with similar characteristics and 
adverse effects (e.g., headache, nausea, and 
vomiting), but the frequency and severity of 
adverse effects appear to be lower for 
cabergoline. Although both drugs are effective in 
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treating hyperprolactinemia, 12 % patients 
cannot tolerate bromocriptine [4]. 
 
Traditional Chinese medicine uses Radix 
bupleuri extract (RBE) to treat 
hyperprolactinemia without the toxic side effects 
associated with conventional anti-
hyperprolactinemia agents. In a previous study, 
we found that RBE decreased prolactin levels in 
hyperprolactinemic mice [5]. However, the 
mechanism underlying the anti-
hyperprolactinemia effects of RBE require further 
investigation. 
 
Most conventional anti-hyperprolactinemia 
agents decrease prolactin secretion through the 
hypothalamic dopaminergic system, and these 
effects are mediated via the cyclic adenosine 
monophosphate (cAMP)/protein kinase A (PKA) 
pathway [6]. In this study, we hypothesized that 
RBE alleviates hyperprolactinemia through 
modulation of the dopamine D2 receptor. We 
investigated the effects of RBE on protein levels 
of dopamine D2 receptor, PKA, and cAMP in the 




Preparation of RBE 
 
Samples of Radix bupleuri were collected in May 
2015 in Bozhou City, Anhui Province, China. 
Taxonomic identification of the plant was 
performed by Professor Pei Chen of Changzhi 
Medical College (Shanxi, China). A voucher 
specimen (No. RBE 201505034) was deposited 
in Changzhi Medical College for future reference.  
One batch of R. bupleuri was dried in an oven. 
An aqueous extract of RBE was prepared by 
steeping the dried R. bupleuri in hot water (60 
°C) three times (1 h each time). The extract was 
dried first in an oven and then freeze-dried. The 
yield was 62.5 % (1 g powder was obtained from 




Female Wistar rats, weighing 200–220 g, were 
obtained from Shanxi Center for Disease Control 
and Prevention (Taiyuan, Shanxi). The animals 
had free access to food and water and were 
allowed to acclimatize for at least 1 week before 
experimental procedures. All experiments were 
approved by the Animal Care and Use 
Committee of Zhejiang Cancer Hospital 
(approval ref no. 20120622) and were carried out 
in compliance with Directive 2010/63/EU on the 
handling of animals used for scientific purposes 
[7]. 
The rats were treated with metoclopramide (150 
mg/kg administered intraperitoneally daily for 10 
days), a dopamine inhibitor widely used to 
generate animal models of hyperprolactinemia 
[8,9]. A total of 60 rats were divided into six 
groups (n = 10 per group): rats that did not 
receive metoclopramide (healthy controls), rats 
that received metoclopramide only (untreated 
hyperprolactinemic rats), hyperprolactinemic rats 
treated with 0.6 mg/kg bromocriptine (positive 
controls), and hyperprolactinemic rats treated 
with a high, medium, or low dose of RBE (19.2 
g/kg, 9.6 g/kg, or 4.8 g/kg, respectively). The 
drugs were dissolved in 2 mL water and 
administered by intragastric gavage; healthy 
control and untreated hyperprolactinemic rats 
received 2 mL distilled water. RBE dosages were 
calculated from the human dosage based on 
body surface area. The mice were treated for 30 
days. 
 
Western blot analysis  
 
To determine hypothalamic dopamine D2 
receptor protein levels after the 30-day treatment 
period, rat hypothalamus tissues were 
homogenized in RIPA buffer with protease 
inhibitor (cOmplete EDTA-free protease inhibitor 
cocktail tablets; Roche Applied Science, 
Mannheim, Germany) and centrifuged at 3000 × 
g for 15 min at 4 °C. The supernatant was 
centrifuged at 12,000 × g for 20 min at 4 °C, and 
the samples were then diluted in RIPA buffer and 
loading buffer. After separation by 12 % sodium 
dodecyl sulfate polyacrylamide gel 
electrophoresis, the proteins were transferred 
onto polyvinylidene difluoride membranes 
(Merck). Nonspecific protein-binding sites were 
blocked by incubating with phosphate-buffered 
saline containing 0.1 % Tween-20 and 5 % fat-
free milk for 1 h at room temperature, followed by 
incubation with primary antibodies against 
dopamine receptor D2 (1:1000) and ß-actin 
(1:5000), which served as a loading control. The 
membranes were then incubated with lumiGLO 
reagent (Cell Signaling Technology) and 
exposed to x-ray film (Kodak, Stamford, CT, 
USA). Protein bands were quantified by ImageJ 
(National Institutes of Health, Bethesda, MD, 
USA). Relative D2 receptor protein levels were 
determined by normalization to ß-actin. 
 
Enzyme-linked immunosorbent assay  
 
To determine hypothalamic cAMP and PKA 
protein levels after the 30-day treatment, rat 
brains were stripped of membranes and blood 
vessels, homogenized, and then centrifuged for 
15 min at 3000 r·min-1. Protein levels of PKA and 
cAMP in the supernatant were then determined 
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by enzyme-linked immunosorbent assay (ELISA; 





Treatment groups were compared by one-way 
analysis of variance (ANOVA), followed by 
Student–Newman–Keuls post hoc test for 
multiple comparisons. Data are expressed as 





Effects of RBE on hypothalamus dopamine 
D2 receptor levels in hyperprolactinemic rats 
 
Results of western blot analysis showed that 
hypothalamus dopamine D2 receptor protein 
levels were considerably lower in untreated 
hyperprolactinemic rats than in healthy controls 
(p < 0.01). As expected, this decrease was 
attenuated by 30-day treatment with 0.6 mg/kg 
bromocriptine (positive control, p < 0.01). 
Treatment with RBE resulted in a dose-
dependent decrease in dopamine D2 receptor 
levels (4.8 g/kg, p < 0.05; 9.6 g/kg, p < 0.01; 19.2 
g/kg, p < 0.01) (Fig. 1). 
 
Effect of RBE on hypothalamus PKA and 
cAMP levels in hyperprolactinemic rats  
 
Results of ELISA showed that hypothalamus 
levels of PKA and cAMP were significantly higher 
in hyperprolactinemic rats compared with healthy 
controls (p < 0.01). This upregulation of PKA and 
cAMP protein expression was attenuated by 
treatment with bromocriptine (p < 0.01). 
Treatment with RBE resulted in a dose-
dependent decrease in PKA and cAMP levels 
(4.8 g/kg, p < 0.05; 9.6 g/kg, p < 0.01; 19.2 g/kg, 




In a previous study, we found that RBE 
significantly decreased prolactin levels in a 
mouse model of hyperprolactinemia. In the 
present study, we investigated the mechanism 
underlying the anti-hyperprolactinemia effects of 
RBE and found that RBE significantly increased 
dopamine D2 receptor protein levels and 
significantly decreased cAMP and PKA protein 
levels in the hypothalamus of hyperprolactinemic 
rats. 
 
Dopamine receptors are members of the G-
protein coupled receptor family [10-12] and are 
classified on the basis of their effect on adenylyl 




Figure 1: Elevated hypothalamus dopamine D2 receptor (DRD2) levels in metoclopramide-induced 
hyperprolactinemic rats (Model) were decreased in a dose-dependent manner by Radix bupleuri extract (RBE). 
Results were analyzed by one-way ANOVA and expressed as mean ± SEM (n = 10). *p < 0.05 and **p < 0.01 
compared with untreated hyperprolactinemic rats. Control = healthy rats; BMT = bromocriptine-treated 
hyperprolactinemic rats 
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Figure 2: Decreased hypothalamus PKA and cAMP levels in metoclopramide-induced hyperprolactinemic rats 
(Model) were dose-dependently increased after 30-day treatment with Radix bupleuri extract (RBE). Results were 
analyzed by one-way ANOVA and expressed as mean ± SEM (n = 10). *p < 0.05 and **p < 0.01 compared with 
untreated hyperprolactinemic rats. Control = healthy rats; BMT = bromocriptine-treated hyperprolactinemic rats 
 
D1-like dopamine receptors (D1 and D5) couple 
primarily to Gαs and increase intracellular levels 
of the second messenger cAMP and upregulate 
the activity of PKA. By contrast, D2-like 
dopamine receptors (D2, D3, and D4) couple to 
Gαi/o and decrease levels of cAMP, thereby 
suppressing PKA activity [13–15]. 
 
In the adenohypophysis, which secretes 
prolactin, the predominant dopamine receptor is 
the D2 receptor [16-18]. In a pituitary cell line 
transfected with the gene encoding the dopamine 
D2 receptor, treatment with dopamine decreased 
intracellular cAMP levels and inhibited prolactin 
secretion [19,20]. Similarly, most conventional 
anti-hyperprolactinemia agents are D2 receptor 
agonists, which decrease prolactin secretion 
through cAMP/PKA signaling. In this study, RBE 
increased dopamine D2 receptor levels and 
decreased cAMP and PKA levels in the 
hypothalamus of hyperprolactinemic rats 
significantly. These results suggest that the anti-
hyperprolactinemic activity of RBE is mediated 





Radix bupleuri extract decreases prolactin 
secretion in hyperprolactinemic rats via 
dopamine D2 receptor and cAMP/PKA signaling. 
This mechanism is similar to that of conventional 
treatments for hyperprolactinemia, without the 
toxic side effects. This traditional Chinese 
medicine may, therefore, be useful for the 
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